Cellectis: 58% Complete Response Rate for Cema-cel, a Key Milestone in the ALPHA3 Trial
Cellectis' flagship program records an intermediate clinical success. The futility analysis of the pivotal ALPHA3 trial, conducted by its partner Allogene, shows that 58.3% of patients receiving cema-cel achieved a complete response in terms of minimal residual disease, surpassing reference thresholds from the literature. However, this result is based on a limited number of patients and regulatory approval is not expected until 2028 at the earliest.
Detailed Results from the ALPHA3 Trial
Allogene Therapeutics revealed the results of the intermediate futility analysis of the ALPHA3 trial concerning cema-cel, the candidate product licensed to Servier and then sublicensed to Allogene in certain territories. This analysis, triggered at the 24th patient completion, involved a total of 24 patients. In the cema-cel arm, 58.3% of patients (7 out of 12) achieved minimal residual disease negativity on day 45, compared to 16.7% (2 out of 12) in the observation group. This absolute difference of 41.6% in terms of minimal residual disease clearance substantially exceeds the thresholds from medical literature, where a difference of 25 to 30% could translate into a significant clinical benefit. In terms of safety, cema-cel was generally well tolerated: 10 out of 12 patients were managed on an outpatient basis after infusion, with no cytokine release syndrome, no immune effector cell-associated neurotoxicity syndrome, no graft-versus-host disease, and no serious adverse events related to the treatment.
Interpretation of Interim Results
Cellectis' press release specifies that these interim results are based on a limited number of patients and should not be considered predictive of the final results of the ALPHA3 study or other clinical trials. This caution reflects a standard practice in the interpretation of early clinical data. Cema-cel, derived from the UCART19 product initially developed by Cellectis, is an allogeneic anti-CD19 CAR-T therapy. Unlike autologous CAR-T therapies, which are made from each patient's T lymphocytes, cema-cel is derived from T lymphocytes of healthy donors, which should theoretically speed up manufacturing, improve accessibility, and standardize the product.
Future Steps and Financial Milestones
Allogene indicated that patient recruitment for the study is expected to be completed by the end of 2027. An interim analysis of event-free survival is scheduled for mid-2027, followed by a main analysis in mid-2028. If these results prove positive, Allogene could support the submission of a marketing authorization application. As part of the licensing agreement with Servier, Cellectis is eligible to receive up to $340 million in development and sales milestone payments, as well as double-digit royalties on net sales of licensed CD19 products, including cema-cel. However, these financial milestones remain contingent upon the success of later phases of clinical trials and regulatory approval.
